Our PRODUCTS

Simplified Research that resonates to the ever-evolving market conditions.

Low-To-Medium Risk

This report category provides investors with a low to moderate risk tolerance an opportunity to recognize quality equity stocks from a medium to long-term perspective.

Earnings Hunter Report
Earnings Hunter Report

Kalkine’s Earnings Hunter Report enlightens the general philosophy of safeguarding investors’ interests with insights on stocks typically having proven track record of earnings performance and strong potential.

Kalkine IPO Report
Kalkine IPO Report

Kalkine IPO Report provides an in-depth analysis of the most popular and attractive global IPOs waiting to hit the street.

Global Big Money Report
Global Big Money Report

Featuring high-quality mid-cap to blue-chip stocks with medium and long-term investment horizon. The product caters to investors, including affluent and High-Net-Worth individuals. The stock selection maintains a balance of conservative and aggressiv

Healthcare Report
Healthcare Report

The growing significance of investment in the healthcare sector is here to stay. The report highlights LSE-Listed healthcare service providers, including pharma, biotech, medtech, medical imaging, medical IT start-ups, and medicinal cannabis etc.

KALIN®
KALIN®

With investment for medium-to-long-term, we cover stocks in diversified sectors that are undervalued and may have the potential for value generation alongside providing shareholder returns in the form of dividends, and or buy backs.

Dividend Income Report
Dividend Income Report

With yields fall back on quantitative easing by major economies to combat the COVID-19, our dividend income report captures stocks that pays consistent dividends and stable business models with predictable cash flows.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and
Terms and Conditions
Allow cookies Decline